Nuclear medicine poised to reach $12 billion by 2025
Nuclear medicines, a key in diagnostics and therapeutics including treatment for cancer and cardiac disorders, are continuing to gain traction in the medical world. It’s predicted that the global nuclear medicine market will grow from 6.5 billion USD in 2017 to 12.41 billion by 2025, according to a report by Fior Markets.
The increasing number of new cancer cases and the rise in cardiovascular diseases driven by an aging population are playing into this growth, along with investments by major players in the field. Key market participants include Bracco Imaging S.p.A, GE Healthcare, Eckert & Ziegler Group, Cardinal Health, and others. Leading companies in nuclear medicine are currently acquiring other players to increase their footprints in the market. With the oncology sector dominating the nuclear medicine market, the secondary focus is on diagnostics, which is expected to grow with the highest CAGR (8.91%) during the forecast period of 2018-2025.